A phase II study of sunitinib malate (Sutent) and chemoembolization in patients with unresectable hepatocellular cancer.

Trial Profile

A phase II study of sunitinib malate (Sutent) and chemoembolization in patients with unresectable hepatocellular cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs Sunitinib (Primary) ; Doxorubicin
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2012 Planned end date changed from 1 Jan 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 30 May 2012 Planned End Date changed from 1 Mar 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Planned end date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top